Track Steminent Biotherapeutics's long-term debt ($46M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (September 2026), 7729.TWO shows a long-term debt of $46M. Scroll down for historical charts and peer comparison views.
Tracking 7729.TWO's long-term debt over time shows whether Steminent Biotherapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $46M Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this long-term debt page, Stockcircle has Steminent Biotherapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $46M) with ownership activity and broader fundamentals.
Steminent Biotherapeutics's long-term debt is $46M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.